StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Eli Lilly (LLY) PT Maintained at $95 at Cowen on 1Q18 Report; 'Top & Bottom Line Beat... FY18 Guidance Raised'
April 24, 2018 11:50 AM
Cowen maintained its price target on Eli Lilly (NYSE: LLY) at $95.00 while maintaining a ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst EPS Change
Analyst EPS View
Next Articles
Eli Lilly (LLY) PT Raised to $82 at Credit Suisse
April 25, 2018 8:59 AM
Eli Lilly (LLY) PT Lowered to $78 at BMO Capital
April 25, 2018 7:13 AM
Eli Lilly & Co. (LLY) Tops Q1 EPS by 21c, Raises FY EPS Guidance
April 24, 2018 6:27 AM
Eli Lilly & Co. (LLY) & Incyte Corporation (INCY) Confirms FDA Advisory Committee Recommends Approval of Baricitinib 2mg and Against 4mg
April 24, 2018 6:01 AM
FDA Votes 10-5 to Back Incyte (INCY) and Lilly's (LLY) Baricitinib 2 mg, Votes 5-10 Against 4 mg
April 23, 2018 4:54 PM
Amid drug price worries, earnings to test U.S. pharma, biotech shares
April 23, 2018 4:49 PM
Incyte (INCY), Lilly (LLY) Low Dose Baricitinib Wins FDA Panel Vote on Safety; High Does Fails to Win Panel Vote on Safety - Bloomberg
April 23, 2018 4:41 PM
Incyte (INCY), Eli Lilly (LLY) Panel Going More Favorably Than Previously Suggested - RBC
April 23, 2018 12:43 PM
Eli Lilly & Co. (LLY) Reports Additional Top-Line Results from CYRAMZA Phase 3 RANGE Study
April 20, 2018 2:50 PM
